Pharsight

1. List of Besivance drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8481526	BAUSCH AND LOMB	Fluoroquinolone carboxylic acid molecular crystals	Jan, 2031 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8937062	BAUSCH AND LOMB	Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria	Nov, 2029 (6 years from now)
US8604020	BAUSCH AND LOMB	Fluoroquinolone carboxylic acid molecular crystals	Mar, 2030 (7 years from now)
US8415342	BAUSCH AND LOMB	Besifloxacin ophthalmic composition for the treatment or control of infection	Nov, 2030 (7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.6% BASE	SUSPENSION/DROPS;OPHTHALMIC	Prescription

2. List of Prolensa drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129431	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Sep, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927606	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (11 months from now)
US9561277	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (11 months from now)
US8871813	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (11 months from now)
US9144609	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (11 months from now)
US8669290	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (11 months from now)
US8754131	BAUSCH AND LOMB	Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid	Jan, 2024 (11 months from now)
US10085958	BAUSCH AND LOMB	Bromfenac bioavailability	Nov, 2032 (9 years from now)
US9517220	BAUSCH AND LOMB	Bromfenac bioavailability	Nov, 2033 (10 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: Method of treating ocular inflammation; Method of treatment to alleviate inflammation of the eye; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0007	26 Jul, 2013	1		11 Sep, 2025	Non-Forfeiture

Strength	Dosage	Availability
EQ 0.07% ACID	SOLUTION/DROPS;OPHTHALMIC	Prescription

3. List of Vyzulta drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8058467	BAUSCH AND LOMB	Prostaglandin derivatives	Jan, 2025 (1 year, 10 months from now)
US7910767	BAUSCH AND LOMB	Prostaglandin derivatives	Jan, 2025 (1 year, 10 months from now)
US7273946	BAUSCH AND LOMB	Prostaglandin derivatives	Oct, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345	BAUSCH AND LOMB	Prostaglandin derivatives	Jan, 2025 (1 year, 10 months from now)